|
1
|
Vural EM, van Munster BC and de Rooij SE:
Optimal dosages for melatonin supplementation therapy in older
adults: A systematic review of current literature. Drugs Aging.
31:441–451. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Posadzki PP, Bajpai R, Kyaw BM, Roberts
NJ, Brzezinski A, Christopoulos GI, Divakar U, Bajpai S, Soljak M,
Dunleavy G, et al: Melatonin and health: An umbrella review of
health outcomes and biological mechanisms of action. BMC Med.
16(18)2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Navarro-Alarcon M, Ruiz-Ojeda FJ,
Blanca-Herrera RM and Agil A: Antioxidant activity of melatonin in
diabetes in relation to the regulation and levels of plasma Cu, Zn,
Fe, Mn, and Se in Zucker diabetic fatty rats. Nutrition.
29:785–789. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yousaf F, Seet E, Venkatraghavan L,
Abrishami A and Chung F: Efficacy and safety of melatonin as an
anxiolytic and analgesic in the perioperative period: A qualitative
systematic review of randomized trials. Anesthesiology.
113:968–976. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gray C and Ryce A: Melatonin for the
treatment of insomnia: A review of clinical effectiveness,
cost-effectiveness, and guidelines. CADTH (CADTH rapid response
report: summary with critical appraisal), [Internet]. Canadian
Agency for Drugs and Technologies in Health, Ottawa, ON, 2019.
https://www.ncbi.nlm.nih.gov/books/NBK544670/.
February 22, 2019.
|
|
6
|
Grigg-Damberger MM and Ianakieva D: Poor
quality control of over-the-counter melatonin: What they say is
often not what you get. J Clin Sleep Med. 13:163–165.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wright A, Diebold J, Otal J, Stoneman C,
Wong J, Wallace C and Duffett M: The effect of melatonin on
benzodiazepine discontinuation and sleep quality in adults
attempting to discontinue benzodiazepines: A systematic review and
meta-analysis. Drugs Aging. 32:1009–1018. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jarzynka MJ, Passey DK, Johnson DA,
Konduru NV, Fitz NF, Radio NM, Rasenick M, Benloucif S, Melan MA
and Witt-Enderby PA: Microtubules modulate melatonin receptors
involved in phase-shifting circadian activity rhythms: In vitro and
in vivo evidence. J Pineal Res. 46:161–171. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jou MJ, Peng TI, Hsu LF, Jou SB, Reiter
RJ, Yang CM, Chiao CC, Lin YF and Chen CC: Visualization of
melatonin's multiple mitochondrial levels of protection against
mitochondrial Ca (2+)-mediated permeability transition and beyond
in rat brain astrocytes. J Pineal Res. 48:20–38. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Acuña-Castroviejo D, Escames G, Venegas C,
Díaz-Casado ME, Lima-Cabello E, López LC, Rosales-Corral S, Tan DX
and Reiter RJ: Extrapineal melatonin: Sources, regulation, and
potential functions. Cell Mol Life Sci. 71:2997–3025.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tan DX and Reiter RJ: Mitochondria: The
birth place, battle ground and the site of melatonin metabolism in
cells. Melatonin Res. 2:44–66. 2019.
|
|
12
|
Emet M, Ozcan H, Ozel L, Yayla M, Halici Z
and Hacimuftuoglu A: A review of melatonin, its receptors and
drugs. Eurasian J Med. 48:135–141. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Andersen LP, Werner MU, Rosenberg J and
Gögenur I: A systematic review of peri-operative melatonin.
Anaesthesia. 69:1163–1171. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
St Louis EK and Boeve BF: REM sleep
behavior disorder: Diagnosis, clinical implications, and future
directions. Mayo Clin Proc. 92:1723–1736. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Agostoni C, Bresson JL, Fairweather-Tait
S, et al: EFSA panel on dietetic products, N. and allergies.
Scientific opinion on the substantiation of a health claim related
to melatonin and reduction of sleep onset latency (ID 1698, 1780,
4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.
EFSA J. 9(2241)2011.
|
|
16
|
Ma X, Idle JR, Krausz KW and Gonzalez FJ:
Metabolism of melatonin by human cytochromes p450. Drug Metab
Dispos. 33:489–494. 2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhdanova IV, Wurtman RJ, Regan MM, Taylor
JA, Shi JP and Leclair OU: Melatonin treatment for age-related
insomnia. J Clin Endocrinol Metab. 86:4727–4730. 2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Besag FMC, Vasey MJ, Lao KSJ and Wong ICK:
Adverse events associated with melatonin for the treatment of
primary or secondary sleep disorders: A systematic review. CNS
Drugs. 33:1167–1186. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Abbasi B, Kimiagar M, Sadeghniiat K,
Shirazi MM, Hedayati M and Rashidkhani B: The effect of magnesium
supplementation on primary insomnia in elderly: A double-blind
placebo-controlled clinical trial. J Res Med Sci. 17:1161–1169.
2012.PubMed/NCBI
|
|
20
|
Akindele OO, Kunle-Alabi OT, Adeyemi DH,
Oghenetega BO and Raji Y: Effects of vitamin E and melatonin on
serum testosterone level in sleep deprived wistar rats. Afr J Med
Med Sci. 43:295–304. 2014.PubMed/NCBI
|
|
21
|
Nielsen FH: Magnesium, inflammation, and
obesity in chronic disease. Nutr Rev. 68:333–340. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Nutt D, Wilson S and Paterson L: Sleep
disorders as core symptoms of depression. Dialogues Clin Neurosci.
10:329–336. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hruby A, Meigs JB, O'Donnell CJ, Jacques
PF and McKeown NM: Higher magnesium intake reduces risk of impaired
glucose and insulin metabolism and progression from prediabetes to
diabetes in middle-aged americans. Diabetes Care. 37:419–427.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kass LS, Skinner P and Poeira F: A pilot
study on the effects of magnesium supplementation with high and low
habitual dietary magnesium intake on resting and recovery from
aerobic and resistance exercise and systolic blood pressure. J
Sports Sci Med. 12:144–150. 2013.PubMed/NCBI
|
|
25
|
Lemoine P, Wade AG, Katz A, Nir T and
Zisapel N: Efficacy and safety of prolonged-release melatonin for
insomnia in middle-aged and elderly patients with hypertension: A
combined analysis of controlled clinical trials. Integr Blood Press
Control. 5:9–17. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bliwise DL, King AC, Harris RB and Haskell
WL: Prevalence of self-reported poor sleep in a healthy population
aged 50-65. Soc Sci Med. 34:49–55. 1992.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Roth T: Insomnia: Definition, prevalence,
etiology, and consequences. J Clin Sleep Med. 3 (Suppl 5):S7–S10.
2007.PubMed/NCBI
|
|
28
|
Roth T and Roehrs T: Insomnia:
Epidemiology, characteristics, and consequences. Clin Cornerstone.
5:5–15. 2003.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wolkove N, Elkholy O, Baltzan M and
Palayew M: Sleep and aging: 1. Sleep disorders commonly found in
older people. CMAJ. 176:1299–1304. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Marin IM, Petropolou M, Baroiu L, Chirosca
AC, Anghel L and Luca L: Schizophrenia and the family burden during
the pandemic. BRAIN. Broad Research in Artificial Intelligence and
Neuroscience. 11:89–97. 2020.
|
|
31
|
Hardeland R, Poeggeler B, Srinivasan V,
Trakht I, Pandi-Perumal SR and Cardinali DP: Melatonergic drugs in
clinical practice. Arzneimittelforschung. 58:1–10. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhang Y, Zhou XH, Meranus DH, Wang L and
Kukull WA: Benzodiazepine use and cognitive decline in elderly with
normal cognition. Alzheimer Dis Assoc Disord. 30:113–117.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nader D and Gowing L: Is long-term
benzodiazepine use a risk factor for cognitive decline? Results of
a systematic review. J Addict. 24(1569456)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Baroiu L, Dumea E, Năstase F, Niculeț E,
Fotea S, Ciubara AB, Stefanopol IA, Nechita A, Anghel L and Ciubara
A: Assessment of depression in patients with COVID-19 BRAIN. Broad
Research in Artificial Intelligence and Neuroscience. 12:254–264.
2021.
|
|
35
|
Neubauer DN: A review of ramelteon in the
treatment of sleep disorders. Neuropsychiatr Dis Treat. 4:69–79.
2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Stefanopol IA, Miulescu M, Baroiu L,
Anghele AD, Danila DM and Tiron Z: An unusual case of meckel
diverticulitis misdiagnosed as an infected urachal cyst. Medicina.
57(495)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Voicu DF, Anghel L, Baroiu L and Stan D:
About minimal hepatic encephalopathy. BRAIN. Broad Research in
Artificial Intelligence and Neuroscience. 11:70–77. 2020.
|
|
38
|
Sack RL, Lewy AJ, Erb DL, Vollmer WM and
Singer CM: Human melatonin production decreases with age. J Pineal
Res. 3:379–388. 1986.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Karasek M and Reiter RJ: Melatonin and
aging. Neuro Endocrinol Lett. 23 (Suppl 1):S14–S16. 2002.PubMed/NCBI
|
|
40
|
Skene DJ and Swaab DF: Melatonin
rhythmicity: Effect of age and Alzheimer's disease. Exp Gerontol.
38:199–206. 2003.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Scholtens RM, van Munster BC, van Kempen
MF and de Rooij SE: Physiological melatonin levels in healthy older
people: A systematic review. J Psychosom Res. 86:20–27.
2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Fischer TW, Sweatman TW, Semak I, Sayre
RM, Wortsman J and Slominski A: Constitutive and UV-induced
metabolism of melatonin in keratinocytes and cell-free systems.
FASEB J. 20:1564–1566. 2006.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Slominski A, Pisarchik A, Semak I,
Sweatman T, Wortsman J, Szczesniewski A, Slugocki G, McNulty J,
Kauser S, Tobin DJ, et al: Serotoninergic and melatoninergic
systems are fully expressed in human skin. FASEB J. 16:896–898.
2002.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Slominski A, Pisarchik A, Zbytek B, Tobin
DJ, Kauser S and Wortsman J: Functional activity of serotoninergic
and melatoninergic systems expressed in the skin. J Cell Physiol.
196:144–153. 2003.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Tan DX, Manchester LC, Terron MP, Flores
LJ and Reiter RJ: One molecule, many derivatives: A never-ending
interaction of melatonin with reactive oxygen and nitrogen species?
J Pineal Res. 42:28–42. 2007.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Reiter RJ and Tan DX: What constitutes a
physiological concentration of melatonin? J Pineal Res. 34:79–80.
2003.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Reiter RJ, Tan DX and Maldonado MD:
Melatonin as an antioxidant: Physiology versus pharmacology. J
Pineal Res. 39:215–216. 2005.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Tan DX, Manchester LC, Hardeland R,
Lopez-Burillo S, Mayo JC, Sainz RM and Reiter RJ: Melatonin: A
hormone, a tissue factor, an autocoid, a paracoid, and an
antioxidant vitamin. J Pineal Res. 34:75–78. 2003.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kleszczynski K and Fischer TW: Melatonin
and human skin aging. Dermatoendocrinol. 4:245–252. 2012.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Dong K, Goyarts E, Rella A, Pelle E, Wong
YH and Pernodet N: Age associated decrease of MT-1 melatonin
receptor in human dermal skin fibroblasts impairs protection
against UV-induced DNA damage. Int J Mol Sci.
21(326)2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Slominski A, Tobin DJ, Zmijewski MA,
Wortsman J and Paus R: Melatonin in the skin: Synthesis, metabolism
and functions. Trends Endocrinol Metab. 19:17–24. 2008.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Slominski A: Neuroendocrine activity of
the melanocyte. Exp Dermatol. 18:760–763. 2009.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Matsui MS, Pelle E, Dong K and Pernodet N:
Biological rhythms in the skin. Int J Mol Sci.
17(801)2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Tamaru T, Hattori M, Ninomiya Y, Kawamura
G, Varès G, Honda K, Mishra DP, Wang B, Benjamin I, Sassone-Corsi
P, et al: ROS stress resets circadian clocks to coordinate
pro-survival signals. PLoS One. 8(e82006)2013.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Bernerd F and Asselinau D: UVA exposure of
human skin reconstructed in vitro induces apoptosis of dermal
fibroblasts: Subsequent connective tissue repair and implication in
photoaging. Cell Death Differ. 5:792–802. 1998.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kleszczynski K, Hardkop LH and Fisher TW:
Differential effects of melatonin as a broad range UV-damage
preventive dermato-endocrine regulator. Dermatoendocrinol. 3:27–31.
2011.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Fischer TW, Slominski A, Zmijewski MA,
Reiter RJ and Paus R: Melatonin as a major skin protectant: From
free radical scavenging to DNA damage repair. Exp Dermatol.
17:713–730. 2008.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Izykowska I, Cegielski M, Gebarowska E,
Podhorska-Okolow M, Piotrowska A, Zabel M and Dziegiel P: Effect of
melatonin on human keratinocytes and fibroblasts subjected to UVA
and UVB radiation in vitro. In Vivo. 23:739–745. 2009.PubMed/NCBI
|
|
59
|
Aitken GR, Henderson JR, Chang SC, McNeil
CJ and Birch-Machin MA: Direct monitoring of UV-induced free
radical generation in HaCaT keratinocytes. Clin Exp Dermatol.
32:722–727. 2007.PubMed/NCBI View Article : Google Scholar
|
|
60
|
D'Errico M, Lemma T, Calcagnile A, De
Santis LP and Dogliotti E: Cell type and DNA damage-specific
response to human skin cells to environmental agents. Mutat Res.
614:37–47. 2007.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Lee KS, Kim SJ, Ryoo YW and Kim BC:
All-trans-retinoic acid down-regulates elastin promoter activity
elevated by ultraviolet B irradiation in cultured skin fibroblasts.
J Dermatol Sci. 17:182–189. 1998.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Bangha E, Elsner P and Kistler GS:
Suppression of UV-induced erythema by topical treatment with
melatonin (N-acetyl-5-methoxytryptamine). A dose response study.
Arch Dermatol Res. 288:522–526. 1996.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Dreher F, Denig N, Gabard B, Schwindt DA
and Maibach HI: Effect of topical antioxidants on UV-induced
erythema formation when administered after exposure. Dermatology.
198:52–55. 1999.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Slominski AT, Zmijewski MA, Semak I, Kim
TK, Janjetovic Z, Slominski RM and Zmijewski JW: Melatonin,
mitochondria, and the skin. Cell Mol Life Sci. 74:3913–3925.
2017.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Dreher F, Gabard B, Schwindt DA and
Maibach HI: Topical melatonin in combination with vitamins E and C
protects skin from ultraviolet-induced erythema: A human study in
vivo. Br J Dermatol. 139:332–339. 1998.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Fischer TW, Zmijewski MA, Wortsman J and
Slominski A: Melatonin maintains mitochondrial membrane potential
and attenuates activation of initiator (casp-9) and effector
caspases (casp-3/casp-7) and PARP in UVR-exposed HaCaT
keratinocytes. J Pineal Res. 44:397–407. 2008.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Berbinschi S, Baroiu N, Teodor V and
Oancea N: Profiling method of side mill for threading screw for
dental implants. Adv Mat Res. 837:22–27. 2014.
|
|
68
|
Baroiu N, Teodor VG, Berbinschi S, Susac F
and Oancea N: New sharpening method and the behaviour of the
multi-flute twist drill with curved cutting edge in machining
operations. Indian J Eng Mater Sci. 23:357–369. 2016.
|
|
69
|
Tatu AL, Ciobotaru OR, Miulescu M, Buzia
OD, Elisei AH, Mardarea N, Diaconu C, Robu S and Nwabudike LC:
Hydrochlorothiazide: Chemical structure, therapeutic, phototoxic
and carcinogenetic effects in dermatology. Rev Chim. 69:2110–2114.
2018.
|
|
70
|
Nwabudike LC and Tatu AL: Response
to-chronic exposure to tetracyclines and subsequent diagnosis for
non-melanoma skin cancer in a large Mid-Western US population. J
Eur Acad Dermatol Venereol. 32(e159)2018.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Hafsi W, Masood S and Badri T: Actinic
purpura. In: StatPearls [Internet]. StatPearls Publishing, Treasure
Island, FL, 2021.
|
|
72
|
Ceilley RI: Treatment of actinic purpura.
J Clin Aesthet Dermatol. 10:44–50. 2017.PubMed/NCBI
|
|
73
|
Gerber PA, Buhren BA, Schrumpf H, Hevezi
P, Bölke E, Sohn D, Jänicke RU, Belum VR, Robert C, Lacouture ME
and Homey B: Mechanisms of skin aging induced by EGFR inhibitors.
Support Care Cancer. 24:4241–4248. 2016.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Zouboulis CC, Adjaye J, Akamatsu H,
Moe-Behrens G and Niemann C: Human skin stem cells and the ageing
process. Exp Gerontol. 43:986–997. 2008.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Baroiu N, Berbinschi S, Teodor VG, Susac F
and Oancea N: The complementary graphical method used for profiling
side mill for generation of helical surface. Modern technologies in
industrial engineering. IOP Conference Series Materials Science and
Engineering. 227(012013)2017.
|
|
76
|
Kim TK, Lin Z, Tidwell WJ, Li W and
Slominski AT: Melatonin and its metabolites accumulate in the human
epidermis in vivo and inhibit proliferation and tyrosinase activity
in epidermal melanocytes in vitro. Mol Cell Endocrinol. 404:1–8.
2015.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Milani M and Sparavigna A: Antiaging
efficacy of melatonin-based day and night creams: A randomized,
split-face, assessor-blinded proof-of-concept trial. Clin Cosmet
Investig Dermatol. 11:51–57. 2018.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Sagan D, Stepniak J, Gesing A, Lewinski A
and Karbownik-Lewinska M: Melatonin reverses the enhanced oxidative
damage to membrane lipids and improves skin biophysical
characteristics in former-smokers-A study in postmenopausal women.
Ann Agric Environ Med. 24:659–666. 2017.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Bocheva G, Slominski RM and Slominski AT:
Neuroendocrine aspects of skin aging. Int J Mol Sci.
20(2798)2019.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Grossman E, Laudon M and Zisapel N: Effect
of melatonin on nocturnal blood pressure: Meta-analysis of
randomized controlled trials. Vasc Health Risk Manag. 7:577–584.
2011.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Jonas M, Garfinkel D, Zisapel N, Laudon M
and Grossman E: Impaired nocturnal melatonin secretion in
non-dipper hypertensive patients. Blood Press. 12:19–24.
2003.PubMed/NCBI
|
|
82
|
Zeman M, Dulková K, Bada V and Herichová
I: Plasma melatonin concentrations in hypertensive patients with
the dipping and non-dipping blood pressure profile. Life Sci.
76:1795–1803. 2005.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Sakotnik A, Liebmann PM, Stoschitzky K,
Lercher P, Schauenstein K, Klein W and Eber B: Decreased melatonin
synthesis in patients with coronary artery disease. Eur Heart J.
20:1314–1317. 1999.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Waldhauser F, Waldhauser M, Lieberman HR,
Deng MH, Lynch HJ and Wurtman RJ: Bioavailability of oral melatonin
in humans. Neuroendocrinology. 39:307–313. 1984.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Aldhous M, Franey C, Wright J and Arendt
J: Plasma concentrations of melatonin in man following oral
absorption of different preparations. Br J Clin Pharmacol.
19:517–521. 1985.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Paulis L and Simko F: Blood pressure
modulation and cardiovascular protection by melatonin: Potential
mechanisms behind. Physiol Res. 56:671–684. 2007.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Birau N, Peterssen U, Meyer C and
Gottschalck J: Hypotensive effect of melatonin in essential
hypertension. IRCS Med Sci. 9(906)1981.
|
|
88
|
Lusardi P, Preti P, Savino S, Piazza E,
Zoppi A and Fogari R: Effect of bedtime melatonin ingestion on
blood pressure of normotensive subjects. Blood Press Monit.
2:99–103. 1997.PubMed/NCBI
|
|
89
|
Cunnane SC, Manku MS, Oka M and Horrobin
DF: Enhanced vascular reactivity to various agents following
pinealectomy in the rats: Role of melatonin. Can J Physiol
Pharmacol. 58:287–293. 1980.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Koziróg M, Poliwczak AR, Duchnowicz P,
Koter-Michalak M, Sikora J and Broncel M: Melatonin treatment
improves blood pressure, lipid profile,and parameters of oxidative
stress in patients with metabolic syndrome. J Pineal Res.
50:261–266. 2011.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Sewerynek E: Melatonin and the
cardiovascular system. Neuro Endocrinol Lett. 23 (Suppl 1):S79–S83.
2002.PubMed/NCBI
|
|
92
|
Fares A: Night-time exogenous melatonin
administration may be a beneficial treatment for sleeping disorders
in beta blocker patients. J Cardiovasc Dis Res. 2:153–155.
2011.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Altun A and Ugur-Altun B: Melatonin:
Therapeutic and clinical utilization. Int J Clin Pract. 61:835–845.
2007.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Bradley HA, Wiysonge CS, Volmink JA,
Mayosi BM and Opie LH: How strong is the evidence for use of
beta-blockers as first-line therapy or hypertension? Systematic
review and meta-analysis. J Hypertens. 24:2131–2141.
2006.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Scalbert E, Guardiola-Lemaître B and
Delagrange P: Melatonin and regulation of the cardiovascular
system. Therapie. 53:459–465. 1998.PubMed/NCBI(In French).
|
|
96
|
Brismar K, Hylander B, Eliasson K, Rössner
S and Wetterberg L: Melatonin secretion related to side-effects of
beta-blockers from the central nervous system. Acta Med Scand.
223:525–530. 1988.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Brismar K, Mogensen L and Wetterberg L:
Depressed melatonin secretion in patients with nightmares due to
beta-adrenoceptor blocking drugs. Acta Med Scand. 221:155–158.
1987.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Tatu AL, Elisei AM, Chioncel V, Miulescu M
and Nwabudike LC: Immunologic adverse reactions of β-blockers and
the skin. Exp Ther Med. 18:955–959. 2019.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Komatsubara M, Hara T, Hosoya T, Toma K,
Tsukamoto-Yamauchi N, Iwata N, Inagaki K, Wada J and Otsuka F:
Melatonin regulates catecholamine biosynthesis by modulating bone
morphogenetic protein and glucocorticoid actions. J Steroid Biochem
Mol Biol. 165:182–189. 2017.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Torres-Farfan C, Richter HG, Rojas-Garcia
P, Vergara M, Forcelledo ML, Valladares LE, Torrealba F, Valenzuela
GJ and Serón-Ferré M: mt1 Melatonin receptor in the primate adrenal
gland: Inhibition of adrenocorticotropin-stimulated cortisol
production by melatonin. J Clin Endocrinol Metab. 88:450–458.
2003.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Campino C, Valenzuela F, Arteaga E,
Torres-Farfan C, Trucco C, Velasco A, Guzmán S and Serón-Ferré M:
Melatonin reduces cortisol response to ACTH in humans. Rev Med
Chil. 136:1390–1397. 2008.PubMed/NCBI View Article : Google Scholar : (In Spanish).
|
|
102
|
Torres-Farfan C, Valenzuela FJ, Mondaca M,
Valenzuela GJ, Krause B, Herrera EA, Riquelme R, Llanos AJ and
Seron-Ferre M: Evidence of a role for melatonin in fetal sheep
physiology: Direct actions of melatonin on fetal cerebral artery,
brown adipose tissue and adrenal gland. J Physiol. 586:4017–4027.
2008.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Campino C, Valenzuela FJ, Torres-Farfan C,
Reynolds HE, Abarzua-Catalan L, Arteaga E, Trucco C, Guzman S,
Valenzuela GJ and Seron-Ferre M: Melatonin exerts direct inhibitory
actions on ACTH responses in the human adrenal gland. Horm Metab
Res. 43:337–342. 2011.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Tsukamoto N, Otsuka F, Ogura-Ochi K,
Inagaki K, Nakamura E, Toma K, Terasaka T, Iwasaki Y and Makino H:
Melatonin receptor activation suppresses adrenocorticotropin
production via BMP-4 action by pituitary AtT20 cells. Mol Cell
Endocrinol. 375:1–9. 2013.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Hara T, Otsuka F, Tsukamoto-Yamauchi N,
Inagaki K, Hosoya T, Nakamura E, Terasaka T, Komatsubara M and
Makino H: Mutual effects of melatonin and activin on induction of
aldosterone production by human adrenocortical cells. J Steroid
Biochem Mol Biol. 152:8–15. 2015.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Quiros I, Mayo JC, Garcia-Suarez O, Hevia
D, Martin V, Rodríguez C and Sainz RM: Melatonin prevents
glucocorticoid inhibition of cell proliferation and toxicity in
hippocampal cells by reducing glucocorticoid receptor nuclear
translocation. J Steroid Biochem Mol Biol. 110:116–124.
2008.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Zhao CN, Wang P, Mao YM, Dan YL, Wu Q, Li
XM, Wang DG, Davis C, Hu W and Pan HF: Potential role of melatonin
in autoimmune diseases. Cytokine Growth Factor Rev. 48:1–10.
2019.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Niculet E, Chioncel V, Elisei AM, Miulescu
M, Buzia OD, Nwabudike LC, Craescu M, Draganescu M, Bujoreanu F,
Marinescu E, et al: Multifactorial expression of IL-6 with update
on COVID-19 and the therapeutic strategies of its blockade. Exp
Ther Med. 21(263)2021.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Calvo JR and Maldonado MD: The role of
melatonin in autoimmune and atopic diseases. AIMS Mol Sci.
3:158–186. 2016.
|
|
110
|
Nwabudike LC, Miulescu M and Tatu AL: Case
series of an alternative therapy for generalised lichen planus:
Four case studies. Exp Ther Med. 18:943–948. 2019.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu
Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet.
395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Baroiu L, Dumitru C, Iancu A, Leșe AC,
Drăgănescu M, Baroiu N and Anghel L: COVID-19 impact on the liver.
World J Clin Cases. 9:3814–3825. 2021.
|
|
113
|
Juybari KB, Pourhanifeh MH, Hosseinzadeh
A, Hemati K and Mehrzadi S: Melatonin potentials against viral
infections including COVID-19: Current evidence and new findings.
Virus Res. 287(198108)2007.
|
|
114
|
Baroiu N, Baroiu L, Teodor VG and Ciocan
TL: Gaphical method for profiling the side mill which generate
helical flute of tungsten carbide dental cross cut bur. Rev Rom
Mater. 48:131–139. 2018.
|
|
115
|
Shneider A, Kudriavtsev A and Vakhrusheva
A: Can melatonin reduce the severity of COVID-19 pandemic? Int Rev
Immunol. 39:153–162. 2020.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Parlakpinar H, Polat S and Acet HA:
Pharmacological agents under investigation in the treatment of
coronavirus disease 2019 and the importance of melatonin. Fundam
Clin Pharmacol. 35:62–75. 2021.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Tatu AL, Baroiu L, Fotea S, Anghel L,
Polea ED, Nadasdy T, Chioncel V and Nwabudike LC: A working
hypothesis on vesicular lesions related to COVID-19 infection,
koebner phenomena type V, and a short review of related data. Clin
Cosmet Investig Dermatol. 14:419–423. 2021.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Zhang R, Wang X, Ni L, Di X, Ma B, Niu S,
Liu C and Reiter RJ: COVID-19: Melatonin as a potential adjuvant
treatment. Life Sci. 250(117583)2020.PubMed/NCBI View Article : Google Scholar
|
